Oncosil Medical Stock

Oncosil Medical EBIT

The EBIT of Oncosil Medical (OSL.AX) as of Aug 5, 2026 is -15.00 M AUD. In the previous year, EBIT was -11.92 M AUD — a change of 25.84% (lower).

EBIT

-15.00 MAUD

YoY

25.84%

Last updated:

In 2026, Oncosil Medical's EBIT was -15.00 M AUD, a 25.84% increase from the -11.92 M AUD EBIT recorded in the previous year.

The Oncosil Medical EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (k AUD)
Date
EBIT (k AUD)
Jan 1, 2020
-4,340.90 base
Jan 1, 2021
-10,459.40 base
Jan 1, 2022
-10,567.60 base
Jan 1, 2023
-11,272.90 base
Jan 1, 2024
-11,917.60 base
Jan 1, 2025
-14,997.70 base
Jan 1, 2026 (e)
-9,316.45 base
Jan 1, 2027 (e)
0.00 base
YEAREBIT (k AUD)
2027 est -
2026 est -9,316.45
2025 -14,997.70
2024 -11,917.60
2023 -11,272.90
2022 -10,567.60
2021 -10,459.40
2020 -4,340.90
2019 -8,581.60
2018 -8,496.60
2017 -7,053.90
2016 -4,769.80
2015 -2,630.40
2014 -4,440.00
2013 -890.00
2012 -280.00
2011 -390.00
2010 40.00
2009 -450.00
2008 -2,950.00
2007 -1,670.00
2006 -130.00
Access this data via the Eulerpool API

Oncosil Medical Revenue

Oncosil Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.87 M AUD
-4.34 M AUD
-4.26 M AUD
Jan 1, 2021
1.38 M AUD
-10.46 M AUD
-10.43 M AUD
Jan 1, 2022
1.07 M AUD
-10.57 M AUD
-10.73 M AUD
Jan 1, 2023
430,300.00 AUD
-11.27 M AUD
-11.34 M AUD
Jan 1, 2024
583,200.00 AUD
-11.92 M AUD
-11.91 M AUD
Jan 1, 2025
1.26 M AUD
-15.00 M AUD
-15.10 M AUD
Jan 1, 2026 (e)
34.60 M AUD
-9.32 M AUD
-130,240.08 AUD
Jan 1, 2027 (e)
60.50 M AUD
0.00 AUD
0.00 AUD

Oncosil Medical Margins

Oncosil Medical stock margins

The Oncosil Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncosil Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncosil Medical.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-78.62 %
-151.32 %
-148.57 %
Jan 1, 2021
30.40 %
-757.49 %
-755.61 %
Jan 1, 2022
9.42 %
-984.41 %
-999.23 %
Jan 1, 2023
-269.23 %
-2,619.78 %
-2,636.04 %
Jan 1, 2024
-158.88 %
-2,043.48 %
-2,042.80 %
Jan 1, 2025
-78.62 %
-1,188.69 %
-1,196.78 %
Jan 1, 2026 (e)
-78.62 %
-26.92 %
-0.38 %
Jan 1, 2027 (e)
-78.62 %
0.00 %
0.00 %

Oncosil Medical Stock analysis

What does Oncosil Medical do? Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Oncosil Medical's EBIT

Oncosil Medical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oncosil Medical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oncosil Medical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oncosil Medical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oncosil Medical stock

EBIT of Oncosil Medical is -15.00 M AUD in 2026.

EBIT of Oncosil Medical changed from -11.92 M AUD to -15.00 M AUD, representing a 25.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Oncosil Medical since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Oncosil Medical historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Oncosil Medical

All Key Metrics — Oncosil Medical